These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

325 related items for PubMed ID: 23575576

  • 1. Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease.
    Imaeda H, Takahashi K, Fujimoto T, Bamba S, Tsujikawa T, Sasaki M, Fujiyama Y, Andoh A.
    J Gastroenterol; 2014 Jan; 49(1):100-9. PubMed ID: 23575576
    [Abstract] [Full Text] [Related]

  • 2. Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease.
    Bodini G, Giannini EG, Savarino V, Del Nero L, Pellegatta G, De Maria C, Baldissarro I, Savarino E.
    Scand J Gastroenterol; 2016 Sep; 51(9):1081-6. PubMed ID: 27207330
    [Abstract] [Full Text] [Related]

  • 3. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease.
    Mazor Y, Almog R, Kopylov U, Ben Hur D, Blatt A, Dahan A, Waterman M, Ben-Horin S, Chowers Y.
    Aliment Pharmacol Ther; 2014 Sep; 40(6):620-8. PubMed ID: 25039584
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Association between serum adalimumab concentrations and endoscopic disease activity in patients with Crohn's disease.
    Morita Y, Imaeda H, Nishida A, Inatomi O, Bamba S, Sasaki M, Tsujikawa T, Sugimoto M, Andoh A.
    J Gastroenterol Hepatol; 2016 Nov; 31(11):1831-1836. PubMed ID: 27043158
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Prospective Observational Evaluation of Time-Dependency of Adalimumab Immunogenicity and Drug Concentrations: The POETIC Study.
    Ungar B, Engel T, Yablecovitch D, Lahat A, Lang A, Avidan B, Har-Noy O, Carter D, Levhar N, Selinger L, Neuman S, Natour OH, Yavzori M, Fudim E, Picard O, Kopylov U, Chowers Y, Naftali T, Broide E, Shachar E, Eliakim R, Ben-Horin S.
    Am J Gastroenterol; 2018 Jun; 113(6):890-898. PubMed ID: 29867175
    [Abstract] [Full Text] [Related]

  • 9. Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn's Disease.
    Zapater P, Almenara S, Gutiérrez A, Sempere L, García M, Laveda R, Martínez A, Scharl M, Cameo JI, Linares R, González-Navajas JM, Wiest R, Rogler G, Francés R.
    Inflamm Bowel Dis; 2019 Jul 17; 25(8):1357-1366. PubMed ID: 30776076
    [Abstract] [Full Text] [Related]

  • 10. Comparative analysis of the influence of clinical factors including BMI on adalimumab and infliximab trough levels.
    Bond A, Asher R, Jackson R, Sager K, Martin K, Kneebone A, Philips S, Taylor W, Subramanian S.
    Eur J Gastroenterol Hepatol; 2016 Mar 17; 28(3):271-6. PubMed ID: 26657455
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
    Chaparro M, Barreiro-de Acosta M, Echarri A, Almendros R, Barrio J, Llao J, Gomollón F, Vera M, Cabriada JL, Guardiola J, Guerra I, Beltrán B, Roncero O, Busquets D, Taxonera C, Calvet X, Ferreiro-Iglesias R, Ollero Pena V, Bernardo D, Donday MG, Garre A, Godino A, Díaz A, Gisbert JP.
    Dig Dis Sci; 2019 Mar 17; 64(3):846-854. PubMed ID: 30426297
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF.
    Yamada A, Sono K, Hosoe N, Takada N, Suzuki Y.
    Inflamm Bowel Dis; 2010 Nov 17; 16(11):1898-904. PubMed ID: 20310016
    [Abstract] [Full Text] [Related]

  • 15. Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohn's Disease.
    Bodini G, Giannini EG, Furnari M, Marabotto E, Baldissarro I, Del Nero L, Assandri L, Moscatelli A, Savarino V, Savarino E.
    J Gastrointestin Liver Dis; 2015 Dec 17; 24(4):451-6. PubMed ID: 26697571
    [Abstract] [Full Text] [Related]

  • 16. Prediction of Short- and Medium-term Efficacy of Biosimilar Infliximab Therapy. Do Trough Levels and Antidrug Antibody Levels or Clinical And Biochemical Markers Play the More Important Role?
    Gonczi L, Vegh Z, Golovics PA, Rutka M, Gecse KB, Bor R, Farkas K, Szamosi T, Bene L, Gasztonyi B, Kristóf T, Lakatos L, Miheller P, Palatka K, Papp M, Patai Á, Salamon Á, Tóth GT, Vincze Á, Biro E, Lovasz BD, Kurti Z, Szepes Z, Molnár T, Lakatos PL.
    J Crohns Colitis; 2017 Jun 01; 11(6):697-705. PubMed ID: 27838610
    [Abstract] [Full Text] [Related]

  • 17. One-Year Clinical Outcomes in an IBD Cohort Who Have Previously Had Anti-TNFa Trough and Antibody Levels Assessed.
    Tighe D, Hall B, Jeyarajah SK, Smith S, Breslin N, Ryan B, McNamara D.
    Inflamm Bowel Dis; 2017 Jul 01; 23(7):1154-1159. PubMed ID: 28486256
    [Abstract] [Full Text] [Related]

  • 18. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.
    Roblin X, Rinaudo M, Del Tedesco E, Phelip JM, Genin C, Peyrin-Biroulet L, Paul S.
    Am J Gastroenterol; 2014 Aug 01; 109(8):1250-6. PubMed ID: 24913041
    [Abstract] [Full Text] [Related]

  • 19. Influence of combination therapy with immune modulators on anti-TNF trough levels and antibodies in patients with IBD.
    van Schaik T, Maljaars JP, Roopram RK, Verwey MH, Ipenburg N, Hardwick JC, Veenendaal RA, van der Meulen-de Jong AE.
    Inflamm Bowel Dis; 2014 Dec 01; 20(12):2292-8. PubMed ID: 25230167
    [Abstract] [Full Text] [Related]

  • 20. Clinical relevance of innovative immunoassays for serum ustekinumab and anti-ustekinumab antibody levels in Crohn's disease.
    Morita Y, Imai T, Bamba S, Takahashi K, Inatomi O, Miyazaki T, Watanabe K, Nakamura S, Yoshida A, Endo Y, Ohmiya N, Tsujikawa T, Andoh A.
    J Gastroenterol Hepatol; 2020 Jul 01; 35(7):1163-1170. PubMed ID: 31860733
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.